---
title: "Replimune wins FDA skin cancer drug approval on third try. Why the stock is tumbling."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295260899.md"
description: "Replimune secures FDA approval for Tudriqev on its third attempt, making it the company’s first product on the market."
datetime: "2026-08-07T16:54:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295260899.md)
  - [en](https://longbridge.com/en/news/295260899.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295260899.md)
generator: "portal-rs"
---

# Replimune wins FDA skin cancer drug approval on third try. Why the stock is tumbling.

Replimune secures FDA approval for Tudriqev on its third attempt, making it the company’s first product on the market.

### Related Stocks

- [REPL.US](https://longbridge.com/en/quote/REPL.US.md)

## Related News & Research

- [16:20 ETRobbins LLP Urges REPL Investors Who Lost Money Investing in Replimune to Contact the Firm for Information About Leading the Class Action](https://longbridge.com/en/news/296649920.md)
- [Quantinno Capital Management LP Increases Stock Position in Replimune Group, Inc. $REPL](https://longbridge.com/en/news/296198190.md)
- [Replimune grants CCO Michelle DiNapoli options for 150,000 shares at $15.58, plus 100,000 RSUs](https://longbridge.com/en/news/296394220.md)
- [Regeneron Stock (REGN) Buckling as Shareholders Sue Over Cancer Drug Claims](https://longbridge.com/en/news/296616209.md)
- [Moderna's personalized mRNA shot could reshape the fight against skin cancer - but it may also be overhyped](https://longbridge.com/en/news/296527593.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**